TrialNature communications2026
Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study.
Mauro Cives et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it